News and updates

Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients

November 14, 2018

 PRESS RELEASE Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients New data from the trial shows that a subgroup of “ultra-high risk” patients identified by MammaPrint respond better to certain targeted therapies and treatment combinations In a separate…

Read more

Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines

October 9, 2018

PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines The NCCN recommends Agendia’s MammaPrint® breast cancer test with the highest level of evidence for early-stage breast cancer patients with estrogen receptor-positive, lymph-node negative and lymph-node positive (LN+ 1-3)  MammaPrint is now the only genomic…

Read more

Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China

September 18, 2018

For the first time, early-stage breast cancer patients and their physicians in China can access clinically validated and prospectively proven tests for breast cancer risk of recurrence and molecular subtyping IRVINE, CALIF., U.S., AMSTERDAM, NETHERLANDS and BEIJING, CHINA – 18 September 2018 – Agendia, Inc., a world leader in precision oncology, announced that it has…

Read more

US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology

August 23, 2018

Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research IRVINE, CALIF., U.S., THE WOODLANDS, TEXAS, U.S., and AMSTERDAM, NETHERLANDS (23 August 2018) – Agendia, Inc., a world leader in precision oncology, announced today that US Oncology Research, one of the nation’s largest research…

Read more